Similar content being viewed by others Introduction Type 2 diabetes mellitus (T2DM) is a complex clinical syndrome characterized by disrupted glucose metabolism, due to the interplay of genetic and environmental factors
Evidence Summary Current evidence supports the following conclusions: GLP-1 drugs reduce caloric intake Reduced intake may reduce micronutrient consumption Delayed gastric emptying does not equal malabsorption Rapid weight loss may increase lean mass vulnerability Long-term micronutrient outcome data remain limited There is mechanistic plausibility for nutritional risk in certain populations, but no strong evidence of universal depletion across all patients
Not every patient requires the maximum dose
Planting in groups creates a remarkable visual statement
While genetic predisposition does not predict exact medication response, identifying these variants may provide context for why an adolescent is particularly susceptible to weight gain and could inform whether GLP-1 therapy aligns with their underlying biologya nuance that supports more personalized provider conversations
Other effects, some rare, include medullary thyroid carcinoma
